Bordetella pertussis re-emergence - NGS-based RPTM analysis reveals the atypical clinical features of children

百日咳杆菌的再次出现——基于NGS的RPTM分析揭示了儿童的非典型临床特征

阅读:1

Abstract

BACKGROUND: Bordetella pertussis (BP) infection has risen rapidly in pediatrics recently, and next-generation sequencing has significantly improved pertussis’ early diagnosis. High detection rates raise the concern of pertussis re-emergence. We used tNGS to analyze respiratory secretions from children with lower respiratory tract infections, aiming to assess the significance of BP co-detected. METHODS: This study included pediatric patients aged 1 month to 14 years who were hospitalized for lower respiratory tract infections from April 2023 to March 2024. Respiratory secretions were collected and analyzed using tNGS sequencing. Clinical data were collected, including clinical symptoms and laboratory markers. According to tNGS read per ten million (RPTM), pertussis patients were divided into three groups: low RPTM group (< 10,000), medium RPTM group (10,000–25,000), and high RPTM group (> 25,000). The association between pertussis RPTM and clinical characteristics was evaluated. RESULTS: Among the 865 pediatric lower respiratory tract infections, 56 cases (6.47%) were tested BP positive in respiratory secretions using tNGS. Bordetella pertussis primarily affected children over 4 years old and lacked typical clinical symptoms and laboratory markers. All patients with BP infection were co-detected with other common pathogens. The high RPTM group was more common in children under 4 years old, in which pertussis appeared as the predominant pathogen, with a shorter fever duration and lower lung consolidation/pulmonary atelectasis incidence. In contrast, the low-RPTM group was more common in elder children, with prolonged fever, co-infection with mycoplasma pneumoniae, and lung parenchymal lesions. CONCLUSION: Pertussis re-emergence primarily happens to older children who present with atypical clinical features and are co-infected. tNGS RPTM analysis helped identify the dominant pathogen in pertussis infections. CLINICAL TRIAL NUMBER: Not applicable. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-026-12878-7.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。